pattern cursor banner
pattern

posters

view our product related posters published across the globe

cursor
Poster page
Product
Conference :
  • publication
    WCK 5222 [Cefepime-Zidebactam, FEP-ZID]: Mechanistic Basis Behind Novel β-lactam–β-lactam Enhancer Combination Against Metallo-β-lactamase (MBL)-producing E. coli (EC) K. pneumoniae (KP), P. aeruginosa (PA) and its Impact on Therapeutically Relevant Bactericidal Exposures Assessed Through in vitro Pharmacodynamic Modelling (IVPM) and Mouse Lung Eradication Studies
    • WCK 5222
    • ID Week 2016
    • February 8, 17
    View PDF
  • publication
    WCK 4873 (Nafithromycin): Assessment of in vitro Human CYP Inhibitory Potential of a Novel Lactone-ketolide
    • WCK 4873
    • ID Week 2016
    • February 8, 17
    View PDF
  • publication
    Zidebactam Phase 1 Single Ascending Dose and Crossover Study in Healthy Subjects
    • WCK 5222
    • ID Week 2016
    • February 8, 17
    View PDF
  • publication
    WCK 771: A Phase I Safety, Tolerability and Pharmacokinetics of 800 mg Multiple Dose Intravenous Infusion.
    • WCK 771
    • 46th ICAAC, 2006
    • April 4, 16
    View PDF
  • publication
    Pharmacokinetics of Intravenous Levonadifloxacin Administered as WCK 771 in Healthy US Adults
    • WCK 771
    • 55th ICAAC, 2015
    • April 4, 16
    View PDF
  • publication
    Pharmacokinetics of Levonadifloxacin Administered as Intravenous WCK 771 and Oral WCK 2349 in Healthy Indian Male Adults
    • WCK 771
    • 55th ICAAC, 2015
    • April 4, 16
    View PDF
  • publication
    Population Pharmacokinetics of Levonadifloxacin Administered as WCK 2349, a Novel Oral Benzoquinolizine Quinolone Prodrug
    • WCK 2349
    • 55th ICAAC, 2015
    • April 4, 16
    View PDF
  • publication
    WCK 771/2349 Pharmacokinetic-Pharmacodynamic Target Attainment Analyses
    • WCK 2349
    • 55th ICAAC, 2015
    • April 4, 16
    View PDF
  • publication
    Food Effect and Absolute Bioavailability study of WCK 2349 and WCK 771in Healty Adult Human Volunteers in US
    • WCK 2349
    • 55th ICAAC, 2015
    • April 4, 16
    View PDF
  • publication
    The Structure of the Carbapenem-Hydrolyzing Class D ß-Lactamase OXA-24/40 in Complex with Imipenem (IMI): A Novel Binding Conformation
    • 55th ICAAC, 2015
    • April 4, 16
    View PDF
  • publication
    Active Site Loop 3 Defines Substrate Specificity in NDM-1
    • 55th ICAAC, 2015
    • April 4, 16
    View PDF
  • publication
    Using Isothermal Calorimetry (ITC) to Design Boronic Acid Inhibitors (BAIs) of ADC Beta-lactamase
    • 55th ICAAC, 2015
    • April 4, 16
    View PDF
  • publication
    MinION Nanopore Sequencing to Identify Pathogens and Resistance Genes Directly from Urine Specimens
    • 55th ICAAC, 2015
    • April 4, 16
    View PDF
  • publication
    In Vitro Activity of WCK771, a Broad Spectrum Anti-MRSA Benzoquinolizine Subclass of Quinolone Against Five Biodefense Bacterial Pathogens
    • WCK 771
    • 55th ICAAC, 2015
    • April 4, 16
    View PDF
  • publication
    Determination of Tier I Quality Control Ranges for WCK 771
    • WCK 771
    • 55th ICAAC, 2015
    • April 4, 16
    View PDF
  • publication
    Determination of Disk Diffusion Zone and Broth Dilution MIC Correlations, and Broth Dilution versus Agar Dilution MICs for WCK 771
    • WCK 771
    • 55th ICAAC, 2015
    • April 4, 16
    View PDF
  • publication
    In Vitro Activity of WCK 771, a New Benzoquinolizine Quinolone in Development, Against Key Bacterial Groups from the USA and Europe
    • WCK 771
    • 55th ICAAC, 2015
    • April 4, 16
    View PDF
  • publication
    Population Pharmacokinetics of intravenous Levonadifloxacin Administered as WCK 771, a Novel Benzoquinolizine Quinolone
    • WCK 771
    • 55th ICAAC, 2015
    • April 4, 16
    View PDF
  • publication
    Activity of Eravacycline against Carbapenemase-producing Enterobacteriaceae and Acinetobacter baumannii
    • 55th ICAAC, 2015
    • April 4, 16
    View PDF
  • publication
    Comparative Activity of WCK 771 Against S.aureus With Raised Vancomycin and Daptomycin MICs And Other Resistotypes
    • WCK 771
    • April 4, 16
    View PDF
  • publication
    S-(-)-NADIFLOXiCIN Oral Bioavailability and Bioefficacy in Mouse Model of Staphylococcal Septicemiaı
    • WCK 771
    • April 4, 16
    View PDF
  • publication
    S-(-)-NADIFLOXi\CIN Oral Bioavailability and Bioefficacy in Mouse Model of Staphylococcal Septicemiaı
    • WCK 771
    • April 4, 16
    View PDF
  • publication
    Bactericidal Activities of New Quinolones WCK 771 A, WCK 919, and Its Two Isomers WCK 1152 and WCK 1153 Against Vancomycin Resistant Staphylococcus aureus (VRSA)
    • WCK 1152
    • 43rd ICAAC
    • April 1, 16
    View PDF
  • publication
    An Investigational Anti-staphylococcal Fluoroquinolone (FQ) with strong Bactericidal Activity Against Low and High Density cultures
    • WCK 771A
    • 41st ICAAC
    • April 1, 16
    View PDF
  • publication
    Antipneumococcal Activities of WCK 771A and WCK 919 (Two New Quinolones) Compared to 12 Other Agents Against 177 Quinolone-Susceptible Pneumococci.
    • WCK 771A
    • 41st ICAAC
    • April 1, 16
  • publication
    WCK 771 Proposed PK-PD Breakpoint Would Provide Coverage of QRSA (Quinolone Resistant Staphylococcus aureus) with Multiple QRDR (Quinolone Resistance Determining Regions) Mutations.
    • WCK 771
    • 45th ICAAC, 2005
    • October 30, 06
    View PDF
  • publication
    WCK 771 – Intravenous Multiple Dose Phase- I Study
    • WCK 771
    • 45th ICAAC, 2005
    • October 30, 06
    View PDF
  • publication
    Novel Oxazolidinones WCK 2664, WCK 2832, WCK 2924 and WCK 3023: Bone Marrow Safety (BMS) Evaluation.
    • WCK 2664
    • 46th ICAAC, 2006
    • September 27, 06
  • publication
    Activity of Three New Oxazolidinones WCK 3023, WCK 2924, WCK 2832 against 100 Drug
    • WCK 2832
    • 46th ICAAC, 2006
    • September 27, 06
  • publication
    Comparative Activity of Three New Oxazolidinones, WCK 3023, WCK 2924, WCK 2832 Against Drug-Susceptible and -Resistant Streptococcus Pneumoniae.
    • WCK 2832
    • 46th ICAAC, 2006
    • September 27, 06
  • publication
    Novel Oxazolidinones WCK 2832 , WCK 2924 and WCK 3023: Minimum Inhibitory Concentration (MIC), Mutant Prevention Concentration (MPC) and Efficacy Against Staphylococci.
    • WCK 2832
    • 46th ICAAC, 2006
    • September 27, 06
  • publication
    Novel Oxazolidinones WCK 2832, WCK 2924 and WCK 3023: Potency and In vivo Efficacy Against Streptococci.
    • WCK 2832
    • 46th ICAAC, 2006
    • September 27, 06
  • publication
    Novel Oxazolidinones WCK 2832, WCK 2924 and WCK 3023: Antibacterial Characterization Against Enterococci.
    • WCK 2832
    • 46th ICAAC, 2006
    • September 27, 06
  • publication
    WCK 2832, WCK 2924, WCK 3023, Novel Oxazolidinone Compounds: Activity Against Staphylococci.
    • WCK 2832
    • 46th ICAAC, 2006
    • September 27, 06
  • publication
    Synthesis and Antibacterial Activity of Novel 4, 4-Disubstituted Piperidinylphenyl Oxazolidinones.
    • WCK 3023
    • 46th ICAAC, 2006
    • September 27, 06
  • publication
    Efficacy of WCK 771 A in Systemic Infections Caused by MSSA and MRSA, Pharmacodynamic (PD) Parameters at Efficacy Dose and MRSA Eradication from Mouse Vital Organs.
    • WCK 771A
    • 41st ICAAC, 2001
    • September 1, 06
    View PDF
  • publication
    WCK 771 Selects First Step Mutants of S. aureus in DNA Gyrase.
    • WCK 771
    • 45th ICAAC, 2005
    • October 30, 05
    View PDF
  • publication
    WCK 771: Gram-Negatives Breakpoint Determination through IVPM (In Vitro Pharmacokinetic Model) Study Based on Human Pharmacokinetic Parameters.
    • WCK 771
    • 45th ICAAC, 2005
    • October 30, 05
    View PDF
  • publication
    A Phase- I Study of Escalating Single Doses of Intravenous (IV) WCK 771.
    • WCK 771
    • 44th ICAAC, 2004
    • October 30, 04
    View PDF
  • publication
    WCK-1152 and WCK-1153, Novel Quinolone Compounds: Activity against Streptococcus pneumoniae.
    • WCK 1152
    • 43rd ICAAC, 2003
    • September 1, 03
  • publication
    WCK-1152 and WCK-1153, Novel Quinolone Compounds: Activity against Staphylococci.
    • WCK 1152
    • 43rd ICAAC, 2003
    • September 1, 03
  • publication
    Time-Kill Study of the Antistaphylococcal Activity of a New Quinolone, WCK 919, Compared to 5 Other Quinolones.
    • WCK 919
    • 43rd ICAAC, 2003
    • September 1, 03
  • publication
    WCK 1152 and WCK 1153: Triple Targeting 7-Substituted Aminopiperidino-Fluoroquinolones.
    • WCK 1152
    • 43rd ICAAC, 2003
    • September 1, 03
  • publication
    Fluoroquinolones (FQs) WCK 1152, WCK 771 and Derivatives thereof Inhibit Multidrug Efflux Pumps (EP) of P. aeruginosa (PA ), E. coli (EC), S. pneumoniae (SPN) and S. aureus (SA).
    • WCK 1152
    • 43rd ICAAC, 2003
    • September 1, 03
    View PDF
  • publication
    Efficacy of WCK 1152, a Novel Fluoroquinolone, against Fluoroquinolone-Susceptible and -Resistant Streptococcus pneumoniae Strains in a Mouse Pneumonia Model.
    • WCK 1152
    • 43rd ICAAC, 2003
    • September 1, 03
  • publication
    Efficacy of WCK 1152, a Novel Fluoroquinolone, against Legionella pneumophila serogroup 1 in an Experimental Guinea Pig Infection Model.
    • WCK 1152
    • 43rd ICAAC, 2003
    • September 1, 03
  • publication
    Comparative In Vitro Activities of WCK919, WCK1152, and WCK1153, to Other Fluoroquinolones against Quinolone Non-Susceptible Streptococcus pneumoniae.
    • WCK 1152
    • 43rd ICAAC, 2003
    • September 1, 03
  • publication
    WCK 1152 and WCK 1153: Novel Chiral Fluoroquinolones (FQ) with Attractive Anti-Staphylococcal Features.
    • WCK 1152
    • 43rd ICAAC, 2003
    • September 1, 03
  • publication
    WCK 1152 & WCK 1153: Novel Respiratory Chiral Fluoroquinolones (FQs) with High Potency against Fluoroquinolone Resistant Pneumococci (FQR SPN) and Viridans Streptococci (SPV).
    • WCK 1152
    • 43rd ICAAC, 2003
    • September 1, 03
  • publication
    WCK 771: an investigational Fluoroquinolone (FQ) with High Intravenous (i.v.) Tolerability.
    • WCK 771
    • 43rd ICAAC, 2003
    • September 1, 03
    View PDF
  • publication
    WCK 771: a Chiral Benzoquinolizine-2-Carboxylic Acid Arginine Salt Active against Vancomycin Intermediate Staphylococcus aureus (VISA).
    • WCK 771
    • 43rd ICAAC, 2003
    • September 1, 03
    View PDF
  • publication
    Targeting Both Topoisomerase IV and Gyrase to Reduce Mutant Selection
    • 43rd ICAAC, 2003
    • September 1, 03
  • publication
    The Impact of NorA Mediated Efflux on In Vitro and In Vivo Anti-Staphylococcal Efficacy of An Investigational Fluoroquinolone (FQ) WCK 771 A and Other FQs
    • WCK 771A
    • 41st ICAAC, 2001
    • September 1, 03
    View PDF
  • publication
    WCK 771 A – an Investigational Anti-MRSA Fluoroquinolone (FQ) with Potent Concentration Independent Cidal Action and an Unusual Ability to Kill Slow Growing Staphylococci.
    • WCK 771A
    • 41st ICAAC, 2001
    • September 1, 03
    View PDF
  • publication
    Anti-Anaerobic Activity of Two New Quinolones, WCK 771A And WCK 919, Compared to Nine Other Agents.
    • WCK 771A
    • 42nd ICAAC, 2002
    • September 27, 02
  • publication
    WCK 771 – Pharmacodynamic (PD) Parameters for MRSA and VISA (Vancomycin Intermediate S. aureus) Eradication in In Vitro Pharmacokinetic Model (IVPM).
    • WCK 771
    • 42nd ICAAC, 2002
    • September 27, 02
    View PDF
  • publication
    Time-Kill Analysis of the Anti-Pneumococcal Activity of Two New Quinolones, WCK 771A and WCK919, Compared to Five Other Quinolones.
    • WCK 771A
    • 42nd ICAAC, 2002
    • September 27, 02
  • publication
    Selection of Linezolid (LNZ) Resistant Mutants of MSSA, MRSA and Pneumococci in Murine Infections.
    • 42nd ICAAC, 2002
    • September 27, 02
  • publication
    Characterisation of Linezolid Resistant Mutants of Staphylococcus aureus and Streptococcus pneumoniae Isolated from Mouse in Terms of 23S rRNA Mutations.
    • 42nd ICAAC, 2002
    • September 27, 02
  • publication
    WCK 919 – In Vivo Efficacy in Mouse Pneumococcal Meningitis Infection Model (PMIM) and Pneumococcal Lung Infection Model (PLIM).
    • WCK 919
    • 42nd ICAAC, 2002
    • September 27, 02
  • publication
    WCK 771 – Eradication Efficacy for Methicillin Sensitive (MSSA) and Resistant Staphylococcus aureus (MRSA) Skin Abscess.
    • WCK 771
    • 42nd ICAAC, 2002
    • September 27, 02
    View PDF
  • publication
    WCK 919 – A Fluoroquinolone (FQ) with Excellent Potency and Cidal Effect against Viridans streptococci.
    • WCK 919
    • 42nd ICAAC, 2002
    • September 27, 02
  • publication
    WCK 919 – A Fluoroquinolone (FQ) with Potent Activity against Enterococci.
    • WCK 919
    • 42nd ICAAC, 2002
    • September 27, 02
  • publication
    WCK 771A – an Investigational Anti-Staphylococcal Fluoroquinolone (FQ) with Strong Bactericidal Activity against Low- and High- Density Cultures.
    • WCK 771A
    • 41st ICAAC, 2001
    • September 27, 02
    View PDF
  • publication
    WCK 919 – a New Respiratory Fluoroquinolone (FQ) with Potent Antistaphylococcal activity and an Ability to Overcome NorA Mediated FQ Efflux.
    • WCK 919
    • 41st ICAAC, 2001
    • September 27, 02
  • publication
    WCK 919 – a New Fluoroquinolone (FQ) with Excellent Potency for Gram +ve and Gram -ve Anaerobes.
    • WCK 919
    • 41st ICAAC, 2001
    • September 27, 02
  • publication
    WCK 919 – A New Respiratory Fluoroquinolone (FQ) with High In Vitro and In Vivo Potency against FQ Sensitive (FQS) and Resistant (FQR) Streptococci.
    • WCK 919
    • 41st ICAAC, 2001
    • September 27, 02
  • publication
    WCK 771 – Predictive MRSA Eradication through In Vitro Pharmacokinetic Model (IVPM) Based on Human PK.
    • WCK 771
    • 43rd ICAAC, 2003
    • September 1, 02
    View PDF
  • publication
    Activities of WCK 771A and WCK 919, Two Experimental Quinolones, Compared with Five Other Quinolones against Quinolone Susceptible and Resistant Staphylococci.
    • WCK 771A
    • 41st ICAAC, 2001
    • September 1, 01
  • publication
    In Vivo Efficacy of Fluoroquinolone (FQ) WCK 771 A in Thigh Infections Caused by MSSA and MRSA.
    • WCK 771A
    • 41st ICAAC, 2001
    • September 1, 01
    View PDF
  • publication
    WCK 771 A – An Investigational Fluoroquinolone (FQ) with Unusual Property of Retaining Potency in Acidic Medium/Human Urine and Efficacy in Mouse Pyelonephritis Model.
    • WCK 771A
    • 41st ICAAC, 2001
    • September 1, 01
    View PDF
  • publication
    In Vitro and In Vivo Efficacy of an Investigational Fluoroquinolone (FQ) WCK 771 A against Pneumococci.
    • WCK 771A
    • 41st ICAAC, 2001
    • September 1, 01
    View PDF
  • publication
    Oral Bioavailability and Bioefficacy in Mouse Model of Staphylococcal Septicemia
    • 39th ICAAC, 1999
    • September 1, 99
    View PDF